Patient Support Services Contact Us
Expanding Our Mission to Immuno-oncology
More choice without compromise

Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel anti-PD-1 antibody, toripalimab.

Toripalimab is an investigational new drug currently being evaluated by the FDA for commercial distribution in the United States.

About Coherus Immuno-oncology Toripalimab at ASCO 2021

I-O Begins Here: Late-Stage Anti-PD-1 Antibody

Our foundational first step in immuno-oncology begins with Junshi Biosciences’ anti-PD-1 antibody.

Learn More

Expanded Mission. Expanded Pipeline.

Our expanded immuno-oncology pipeline will be funded with cash flows generated by our commercial biosimilar business.

Learn More

Latest News

Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights

Learn More

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Learn More

Coherus BioSciences to Present at the Bank of America Health Care Conference

Learn More

Coherus Issues Statement of Support for Passage of Biosimilar Legislation

WASHINGTON, D.C., April 14, 2021 -- Coherus BioSciences, Inc.’s (“Coherus”, Nasdaq: CHRS), CEO Denny Lanfear today issued a public statement of support regarding the passage of the Advancing Education on Biosimilars Act of 2021 (S.164).

View Now